jrnls.org logo
Submit

BROWSE ALL JOURNALS

SEE ALL 19 JOURNALS
Indian Journal of Pharmaceutical Education and ResearchNOW IN
Article

Characteristics of Patients with Familial Hypercholesterolemia and Acute Coronary Syndrome Prescribed PCSK9 Inhibitors

Samar Zuhair Alshawwa1★, Lama AlRebdi2, Nouf AlMasri2, Mayada AlSuwaid2, Amal Alnajjar3, Reem Bahmaid4, Faisal AlQarni5, Khaled AlMatrafi6, Sadaf Jamal Glani1★ Corresponding author

  1. 1Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, SAUDI ARABIA.
  2. 2Department of PharmD College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, SAUDI ARABIA.
  3. 3Department of Drug and Poison, BSc, MSc Forensic Toxicology, Drug and Poison Information Center Supervisor, Security Forces Hospital, Riyadh, SAUDI ARABIA.
  4. 4Adult Cardiolody Department, BSc, MSc Consultant Clinical Pharmacist, Adult Cardiology, King Fahad Medical City, Riyadh, SAUDI ARABIA.
  5. 5Cardiolody Department, PharmD, BCPS, BCCP Cardiology Clinical Pharmacist, Security Forces Hospital, Riyadh, SAUDI ARABIA.
  6. 6Non-stock Control Department, BSc, MSc Stock Control Pharmacist, Security Forces Hospital, Riyadh, SAUDI ARABIA.

CORRESPONDENCE

Samar Zuhair Alshawwa

Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, SAUDI ARABIA.

szalshawwa@pnu.edu.sa

Received: 24-03-2026; Revised: 08-05-2026; Accepted: 15-07-2026.

Volume 60, Issue 4 · pp. 1713–1719 · PUBLISHED 2026 · DOI: 10.5530/ijper.20261849

View on IJPER original site ↗

ABSTRACT

Background: Patients with Familial Hypercholesterolemia (FH) or statin intolerance are significantly increasing. Therefore, a novel class of lipid-lowering drugs called Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) inhibitors are prescribed for FH patients and statin intolerant. PCSK9 inhibitors are human monoclonal antibodies that slow down the LDL Receptor’s (LDLR) degradation by binding to PCSK9 adjacent to its binding site with LDL receptors, increasing LDL-C uptake and decreasing LDL-C blood level. Objectives: To evaluate the proper prescribing of PCSK9 inhibitors by measuring adherence to ACC/AHA and ESC/EAS guidelines at two tertiary care hospitals; King Fahad Medical City (KFMC), and Security Forces Hospital (SFH) - Riyadh - Saudi Arabia. Materials and Methods: An observational retrospective cohort study was carried out. Researchers included all patients started on PSCK9 inhibitors, specifically evolocumab for the last three years (from 2020 until the end of 2022) at SFH and KFMC. A data collection sheet (Excel sheet) with 51 questions (variables) is considered the primary research tool; the data were collected from the patient's medical files as another tool. Statistical analysis of categorical variables and continuous variables have been done using SPSS version 20 program. p-values less than 0.05 are deemed statistically significant. Results: Of the 201 patients, 142 (70.6%) were eligible for PCSK9 inhibitors treatment in accordance with ACC/AHA and ESC/EAS guidelines criteria. (66.7%) of patients were male, the mean age was (53.67±12.25) and (42.3%) were obese. Clinically, most of the patients had a history of a previous MI (70.1%), and (32.3%) had two major ASCVD. High-risk conditions were (69.2%) with hypertension and (63.2%) with diabetes. LDL-C level after 4-6 weeks of PCSK9 inhibitors initiation, was observed among the 161 (80.1%) cases of the study sample, while the attrition was in 40 (19.9%) cases. Statistical analysis measured a significant 37.1% reduction rate (p-value<0.001) from baseline to 6 weeks’ follow-up LDL-C laboratory confirmed post-treatment effect of PCSK9 inhibitors. The physicians' adherence to the ESC/EAS and ACC/AHA recommendations criteria in prescribing PSCK9 inhibitors was (70.6%). Conclusion: Most physicians adhered to the ESC/EAS and ACC/AHA recommendations criteria in prescribing PCSK9 inhibitors to FH patients and ACS patients. The results show that up to (70.6%) of physicians at King Fahad Medical City (KFMC) and Security Forces Hospital (SFH) adhere to ACC/AHA and ESC/EAS guidelines for prescribing PCSK9 inhibitors to FH patients and ACS patients this adherence was manifested by the number of patients (38%) who attained the LDL-C level≤1.8 mmol/L (≤70 mg/dL).

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Alshawwa, S. Z., AlRebdi, L., AlMasri, N., AlSuwaid, M., Alnajjar, A., Bahmaid, R., AlQarni, F., AlMatrafi, K., & Glani, S. J. (2026). Characteristics of Patients with Familial Hypercholesterolemia and Acute Coronary Syndrome Prescribed PCSK9 Inhibitors. Indian Journal of Pharmaceutical Education and Research, 60(4), 1713–1719. https://doi.org/10.5530/ijper.20261849